Lipoprotein-Associated Phospholipase A2: An Independent Predictor of Coronary Artery Disease Events in Primary and Secondary Prevention

American Journal of Cardiology

Volumn 101, Issue 12 SUPPL., 2008, Pages

  Anderson, Jeffrey L ^a  

^a LDS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; PRAVASTATIN;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; FOLLOW UP; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; OBESITY; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; HUMANS; INFLAMMATION; LIPOPROTEINS, LDL; PREDICTIVE VALUE OF TESTS; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 46349094873     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.04.015     Document Type: Article

References (43)

1. 2 as an independent predictor of coronary heart disease. N Engl J Med 343 (2000) 1148-1155
2. 2 levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 38 (2001) 1302-1306
3. Blankenberg S., Stengel D., Rupprecht H.J., Bickel C., Meyer J., Cambien F., Tiret L., and Ninio E. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res 44 (2003) 1381-1386
4. 2, high-sensitivity C-reactive protein, and risk for incident heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109 (2004) 837-842
5. 2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany (MONICA-Augsburg). Circulation 110 (2004) 1903-1908
6. Winkler K., Abletshauser C., Friedrich I., Hoffmann M.M., Wieland H., and März W. Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes. J Clin Endocrinol Metab 89 (2004) 1153-1159
7. 2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 26 (2005) 137-144
8. 2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 111 (2005) 570-575
9. Winkler K., Winkelmann B.R., Scharnagl H., Hoffman M.M., Grawitz A.B., Nauck M., Bohm B.O., and Marz W. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors. Circulation 111 (2005) 980-987
10. 2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis (HELICOR). Atherosclerosis 182 (2005) 181-188
11. 2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function and hemodynamic stress (KAROLA). Arterioscler Thromb Vasc Biol 26 (2006) 1586-1593
12. 2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J 152 (2006) 997-1003
13. 2 as a risk factor for coronary vascular disease in the elderly (PROSPER). Proceedings from the XIV International Symposium on Atherosclerosis; June 18-22, 2006; Rome, Italy. Abstract page 484.
14. 2 and cardiovascular disease: results from the Cardiovascular Health Study [abstract]. Circulation 113 (2006) E-332
15. 2) independently predicts incident coronary heart disease (CHD) in an apparently healthy older population: the Rancho Bernardo Study [abstract]. Circulation 114 (2006) II-870
16. 2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection-Thrombolysis in Myocardial Infarction) trial. Circulation 113 (2006) 1745-1752
17. 2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem 52 (2006) 1331-1338
18. 2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol 26 (2006) 2517-2522
19. 2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 27 (2007) 2463-2469
20. Robins S.J., Collins D., Nelson J.J., Bloomfield H.E., and Asztalos B.F. Cardiovascular events with increased lipoprotein-associated phospholipase A2 and low high-density lipoprotein-cholesterol. The Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 28 (2008) DOI: 10.1161/ATVBAHA.107.160739
21. 2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Eur Heart J 28 (2007) 699-704
22. 2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II). Clin Res Cardiol 96 (2007) 604-612
23. 2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 27 (2007) 1788-1795
24. 2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol 27 (2007) 1411-1416
25. 2 and myocardial infarction in women. Circulation 116 (2007) II-818 Abstract 3605
26. 2. J Clin Lab Med 26 (2006) 679-697
27. 2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 165 (2005) 2479-2484
28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
29. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) II-30-II-31
30. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., Fadl Y.Y., Fortmann S.P., Myers H.Y., Myers G.L., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
31. Greenland P., Smith Jr. S.C., and Grundy S.M. Improving coronary disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation 104 (2001) 1863-1867
32. Deedwania P.C., Maki K.C., Dicklin M.R., Stone N.J., Ballantyne C.M., and Davidson M.H. Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II). J Cardiometab Syndr 1 (2006) 295-300
33. Hu F.B., Stampfer M.J., Haffner S.M., Solomon C.G., Willett W.C., and Manson J.E. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 25 (2002) 1129-1134
34. 2 is not increased in association with insulin resistance [abstract]. Arterioscler Thromb Vasc Biol 24 (2004) E-67
35. 2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Rev Mol Diagn 7 (2007) 511-517
36. Smith S.C., Allen J., Blair S.N., Bonow R.O., Brass L.M., Fonarow G.C., Grundy S.M., Hiratzka L., Jones D., Krumholz H.M., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 113 (2006) 2363-2372
37. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith S.C., and Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
38. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Loyal S.V., Hill K.A., Pfeffer M.A., and Skene A.M. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
39. Ridker P.M., Cannon C.P., Morrow D., Rifai N., McCabe C.H., Pfeffer M.A., and Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
40. Bogaty P., Brophy J.M., Boyer L., Simard S., Joseph L., Bertrand F., and Dagenais G.R. Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch Intern Med 165 (2005) 221-226
41. Khor L.L., Muhlestein J.B., Carlquist J.F., Horne B.D., Bair T.L., Maycock C.A., and Anderson J.L. Sex- and age-related differences in the prognostic value of C-reactive protein in patients with angiographic coronary artery disease. Am J Med 117 (2004) 657-664
42. 2 predicts 5-year mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen Risk and Cardiovascular Health Study). Clin Chem 53 (2007) 1440-1447
43. 2 measurements in post-myocardial infarction patients: results from the AIRGENE Study Center Augsburg. Clin Chem 54 (2007) 124-130